IRIS
PALLADINI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.684
AS - Asia 8.012
EU - Europa 6.231
SA - Sud America 1.070
Continente sconosciuto - Info sul continente non disponibili 521
AF - Africa 388
OC - Oceania 18
AN - Antartide 1
Totale 29.925
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.098
CN - Cina 3.312
SG - Singapore 1.947
IE - Irlanda 1.480
HK - Hong Kong 984
BR - Brasile 784
IT - Italia 781
RU - Federazione Russa 756
VN - Vietnam 738
DE - Germania 631
FI - Finlandia 617
UA - Ucraina 487
FR - Francia 409
GB - Regno Unito 333
SE - Svezia 260
ZA - Sudafrica 240
CA - Canada 239
IN - India 210
BD - Bangladesh 187
AR - Argentina 90
MX - Messico 84
ES - Italia 81
JP - Giappone 77
PL - Polonia 67
IQ - Iraq 66
TR - Turchia 65
NL - Olanda 57
PK - Pakistan 52
CO - Colombia 50
AT - Austria 46
ID - Indonesia 44
IL - Israele 41
EC - Ecuador 39
VE - Venezuela 39
BE - Belgio 37
CR - Costa Rica 37
PH - Filippine 35
SA - Arabia Saudita 34
JM - Giamaica 33
MA - Marocco 31
HN - Honduras 30
NI - Nicaragua 25
SV - El Salvador 25
LT - Lituania 24
GT - Guatemala 23
CL - Cile 22
CZ - Repubblica Ceca 22
SC - Seychelles 22
AE - Emirati Arabi Uniti 20
GP - Guadalupe 20
GR - Grecia 20
PR - Porto Rico 20
MY - Malesia 19
AU - Australia 18
IR - Iran 18
CW - ???statistics.table.value.countryCode.CW??? 17
TN - Tunisia 17
TT - Trinidad e Tobago 17
UZ - Uzbekistan 17
AL - Albania 16
KZ - Kazakistan 16
TH - Thailandia 16
EG - Egitto 15
PT - Portogallo 14
JO - Giordania 13
KE - Kenya 13
LB - Libano 12
PY - Paraguay 12
UY - Uruguay 12
AZ - Azerbaigian 11
DK - Danimarca 11
RO - Romania 11
BG - Bulgaria 10
EE - Estonia 10
PE - Perù 10
CH - Svizzera 9
ET - Etiopia 9
MU - Mauritius 9
BO - Bolivia 8
KG - Kirghizistan 8
KR - Corea 8
PS - Palestinian Territory 8
DZ - Algeria 7
LV - Lettonia 6
NP - Nepal 6
SK - Slovacchia (Repubblica Slovacca) 6
BS - Bahamas 5
EU - Europa 5
KH - Cambogia 5
NG - Nigeria 5
PA - Panama 5
SY - Repubblica araba siriana 5
BB - Barbados 4
BH - Bahrain 4
BN - Brunei Darussalam 4
CU - Cuba 4
IS - Islanda 4
RS - Serbia 4
AM - Armenia 3
BY - Bielorussia 3
Totale 29.340
Salva come PNG Salva come JPEG
Città #
Dublin 1.479
San Jose 1.478
Chandler 1.326
Ashburn 1.073
Singapore 1.004
Hong Kong 956
Dallas 864
Council Bluffs 785
Jacksonville 669
Beijing 660
Nanjing 570
Boardman 483
Lauterbourg 288
Los Angeles 287
Princeton 266
Ho Chi Minh City 264
Helsinki 263
Lawrence 252
Nanchang 250
Medford 242
Wilmington 216
Johannesburg 207
Hanoi 189
New York 189
Shenyang 181
Changsha 162
Hebei 162
Santa Clara 156
Ann Arbor 143
Buffalo 133
Jiaxing 132
Munich 132
Redondo Beach 122
Tianjin 118
Shanghai 109
Milan 108
Moscow 104
Hangzhou 97
Pavia 93
São Paulo 82
Piscataway 69
Orem 65
Tokyo 65
Woodbridge 65
Montreal 64
Atlanta 62
North Bergen 55
Frankfurt am Main 53
Rome 53
Norwalk 52
Warsaw 52
Brooklyn 50
Columbus 48
Denver 48
London 48
Seattle 48
Toronto 48
Turku 45
Chicago 44
Chennai 43
Phoenix 43
Houston 42
Da Nang 40
Falkenstein 38
The Dalles 38
Nuremberg 37
San Francisco 37
Brussels 34
Charlotte 33
Fairfield 33
Guangzhou 33
Stockholm 33
Pune 32
Naples 30
Haiphong 29
Washington 29
Boston 27
Brasília 27
Poplar 27
San José 26
Amsterdam 25
Baghdad 25
Managua 25
Manchester 25
Mexico City 25
Verona 25
Rio de Janeiro 24
Zhengzhou 24
Ningbo 23
Bologna 22
Des Moines 22
Vienna 22
Ankara 19
Dhaka 19
Florence 19
Kingston 19
San Salvador 19
Curitiba 18
Las Vegas 18
Medellín 17
Totale 18.474
Salva come PNG Salva come JPEG
Nome #
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 232
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 171
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 169
Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families 163
An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: Limit of detection and follow-up of patients with small M-proteins 163
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL 160
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy 151
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 151
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 150
Chronic intestinal pseudo-obstruction secondary to al amyloidosis associated with severe gastroparesis: case report 150
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 149
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. 148
Amyloid typing: immunoelectron microscopy 148
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 147
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 146
AMICA: an electronic patient record specifically designed for an amyloidosis network 145
Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide 145
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 143
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 142
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 139
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 138
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 138
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum 137
A patient with AL amyloidosis with negative free light chain results 137
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 137
Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyKnowledge Representation for Health-Care 137
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 136
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 136
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy 136
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 136
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 135
Bortezomib-induced paralytic ileus is a potential gastrointestinal side-effect of this first-in-class anti-cancer proteasome inhibitor 135
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. 135
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 135
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 134
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 134
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 133
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 133
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 132
Autologous stem cell transplantation following heart transplantation for AL amyloidosis 131
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 131
Nutritional status evaluation of patients affected by al amyloidosis: a pilot study 130
Clotting alterations in primary systemic amyloidosis. 130
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 130
Cardiac light chain amyloidosis: The role of metal ions in oxidative stress and mitochondrial damage 130
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 130
Hereditary amyloidosis 129
Bone marrow amyloidosis. 128
A practical approach to the diagnosis of systemic amyloidoses 128
CT-guided biopsy in the differential diagnosis of Sjogren syndrome associated cystic lung disease: A case of lung nodular AL-k amyloidosis 127
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 126
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 126
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 125
4D flow evaluation of blood non-Newtonian behavior in left ventricle flow analysis 125
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 124
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 124
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 123
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 122
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 122
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 121
Holter monitoring in AL amyloidosis: prognostic implications. 121
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 121
A workflow management system for the biological samples exchange within the amyloidosis network 121
Biochemical markers in early diagnosis and management of systemic amyloidoses 120
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis 120
Prognostication of survival and progression to dialysis in AA amyloidosis 120
AMICA: an electronic patient record specifically designed for an amyloidosis network. 119
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 119
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 119
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 118
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis 118
Sjögren’s syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? 118
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 118
Comparison of Four-Dimensional Magnetic Resonance Imaging Analysis of Left Ventricular Fluid Dynamics and Energetics in Ischemic and Restrictive Cardiomyopathies 118
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44 116
Thalidomide plus intermediate-dose dexametasone is an effective but toxic treatment for patients with AL (primary) amyloydosis 116
An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis 116
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 115
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin in primary amyloidosis (AL) 115
Proteotoxicity in cardiac amyloidosis: Amyloidogenic light chains affect the levels of intracellular proteins in human heart cells 115
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 114
Valore prognostico della presenza di disturbi della conduzione cardiaca nei pazienti affetti da amiloidosi AL 114
Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis 113
A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options 113
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 112
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis. 112
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma 112
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 112
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 112
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in- class anticancer proteasome inhibitor. 112
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 111
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 111
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 111
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 111
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 109
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 109
Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue 109
Light chain amyloidosis 2012: a new era. 108
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy 107
Clinical aspects of systemic amyloid diseases. 107
Totale 12.930
Salva come PNG Salva come JPEG
Categoria #
all - tutte 133.781
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 133.781
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.034 0 0 0 0 32 19 11 91 61 42 155 623
2022/20233.826 436 278 47 286 351 350 24 211 1.690 20 85 48
2023/20241.412 181 304 48 109 126 295 33 86 12 43 100 75
2024/20254.073 85 295 96 111 70 283 201 254 990 181 479 1.028
2025/202610.875 774 723 1.049 1.208 1.432 419 1.949 518 1.032 786 480 505
2026/20273.870 363 596 836 1.349 726 0 0 0 0 0 0 0
Totale 29.925